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Animal studies have suggested neuropeptide S (NPS) and its receptor (NPSR) to be involved in
the pathogenesis of anxiety-related behavior. In this study, a multilevel approach was applied
to further elucidate the role of NPS in the etiology of human anxiety. The functional NPSR A/T
(Asn107Ile) variant (rs324981) was investigated for association with (1) panic disorder with and
without agoraphobia in two large, independent case–control studies, (2) dimensional anxiety
traits, (3) autonomic arousal level during a behavioral avoidance test and (4) brain activation
correlates of anxiety-related emotional processing in panic disorder. The more active NPSR
rs324981 T allele was found to be associated with panic disorder in the female subgroup of
patients in both samples as well as in a meta-analytic approach. The T risk allele was further
related to elevated anxiety sensitivity, increased heart rate and higher symptom reports during
a behavioral avoidance test as well as decreased activity in the dorsolateral prefrontal, lateral
orbitofrontal and anterior cingulate cortex during processing of fearful faces in patients with
panic disorder. The present results provide converging evidence for a female-dominant role of
NPSR gene variation in panic disorder potentially through heightened autonomic arousal and
distorted processing of anxiety-relevant emotional stimuli.
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Introduction
Neuropeptides have been suggested to have a pivotal
role in the pathogenesis of stress, arousal and anxiety.
In particular, there is converging evidence from
animal studies and molecular genetic studies in
humans for neuropeptide S (NPS) and its cognate
receptor (NPSR) to be involved in the mediation of
anxiety-related behavior and anxiety disorders. NPS,
a 20 amino-acid peptide, acts as an agonist at the
G-protein-coupled NPSR increasing free intracellular
calcium and cyclic adenosine monophosphate
accumulation.1–3
In rodent models, NPS or NPSR agonists have been
observed to elicit a robustly increased arousal as
indicated by hyperlocomotion, righting reflex and
wakefulness.3–5 Interestingly, these arousal promoting
effects seem to be paralleled by an anxiolytic-like
profile of NPS because centrally administered NPS
has been shown to increase the time mice spentReceived 3 March 2010; revised 5 May 2010; accepted 6 June 2010
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exploring less protected or brighter areas of their
environment (for example, open field, four-plate test,
elevated plus maze, elevated zero maze, light-dark
box).3–5 An overall anxiolytic effect of NPS has
furthermore been shown with NPS significantly
reducing the time mice spent burying unfamiliar
objects (defensive marble-burying test).3,6 NPS also
seems to reduce the physiological response to stress
as shown by attenuation of stress-induced hyperther-
mia in mice.4,5 Consistently, NPSR knockout mice
were found to exhibit increased anxiety-like behavior,
and accordingly reduced exploratory activity.7 On
an anatomical level, NPS has been shown to be
expressed in the amygdaloid complex8 and exert a
modulatory effect on both afferent and intrinsic
transmission in amygdala networks in rodent mod-
els.9–11 On a cellular level, NPS increases glutamater-
gic transmission to intercalated GABAergic neurons
in the amygdala conferring an inhibitory influence on
the central amygdaloid nucleus and thereby attenuat-
ing anxiety-like responses.9 Given the crucial role of
the amygdala in the elicitation and regulation of
anxiety-related responses12–14 and increased amygda-
la activity in patients with anxiety disorders,15–18 this
finding underlines the importance of NPS in the
processing of acute fear. In addition, acute adminis-
tration of caffeine, which is a potent anxiogenic and
arousal-increasing substance in many participants,19
has been observed to induce a marked decrease in
mRNA levels of NPS itself, but to upregulate NPSR
expression levels in the brain stem.20 Finally, NPS can
selectively inhibit the release of serotonin and
norepinephrine in the frontal cortex,21 which might
constitute another mechanism through which NPS
modulates anxiety- and arousal-related behavior.
The human NPSR gene is located on chromosome
7p14.3 and comprises at least nine exons. The
chromosomal region 7p14-15 has been previously
found to be linked to panic disorder,22–24 rendering
the NPSR gene a promising functional and positional
candidate gene. An A/T single-nucleotide polymorph-
ism (rs324981) at position 107 of the NPSR gene
leading to an amino-acid exchange from Asn to Ile
(N107I) is of functional relevance with the T allele
(Ile107) increasing NPSR expression and NPS efficacy
at NPSR about tenfold.25,26 Homozygosity for the less
active A allele (Asn107) was found to be under-
represented in the male (n=51) subgroup of 140
Japanese panic disorder patients, suggesting the
higher active T (Ile107) allele to constitute a risk factor
for panic disorder.27
In this study, a multilevel approach was applied to
further elucidate the role of NPS in the pathogenesis
of human anxiety. In detail, it was investigated
whether the functional NPSR A/T (Asn107Ile) variant
(rs324981) was associated (1) with the categorical
phenotype of panic disorder with and without
agoraphobia in two independent, large and well-
controlled case–control studies; (2) with participants’
scores on dimensional anxiety traits such as anxiety
sensitivity; (3) with autonomic arousal level as
reflected by heart rate and symptom ratings during a
behavioral avoidance test (BAT) and (4) with brain
activation correlates of anxiety-related emotional
processing in patients with panic disorder with and
without agoraphobia.
Materials and methods
Association studies with panic disorder and
dimensional anxiety traits
Samples. The discovery sample (ascertained in
Mu¨nster, Munich, Wu¨rzburg, Bonn and Go¨ttingen
and hereafter termed MMWBG sample) comprised
499 unrelated German patients with panic disorder
(women 312, men 187; mean age 38.14±11.61 years;
panic disorder with agoraphobia: 75.7%). The
diagnosis of panic disorder was ascertained by
experienced psychiatrists on the basis of medical
records and structured clinical interviews (SADS-LA
(Schedule for Affective Disorders and Schizophrenia–
Lifetime, Anxiety), CIDI (Composite International
Diagnostic Interview), SKID-I (Strukturiertes
Klinisches Interview fu¨r DSM-IV, Achse-I))
according to the criteria of Diagnostic and Statistical
Manual of Mental Disorders (DSM)-III-R or DSM-IV,
respectively.28–30 Patients with bipolar disorder,
schizophrenia, mental retardation, neurological or
neurodegenerative disorders impairing psychiatric
evaluation were not included in this analysis. Data
regarding comorbid depression were available for
497 of these patients, of whom 15% suffered from a
comorbid major depressive episode. The control
group consisted of 499 unrelated anonymous blood
donors of German descent (women 312, men 187;
mean age 40.01±12.55 years), who due to anonymity
requirements could not be controlled for the presence
of mental diseases. The study was approved of by the
respective local ethical committees and informed
consent was obtained from all participating subjects.
The replication sample is a subsample of patients
from the mechanisms of action in cognitive-behavior-
al therapy (MAC) study in patients with panic
disorder with agoraphobia31 obtained from the BMBF
‘Panic Network’ consisting of 277 of the total 369
included patients. In the patient sample (n=277,
women 209, men 68; mean age 36.40±10.96 years),
the diagnosis of panic disorder with agoraphobia
was established by a structured clinical interview and
verified by clinical interview (CIDI) according to
DSM-IV criteria.30 Patients with bipolar disorder,
schizophrenia, mental retardation, neurological and
neurodegenerative disorders were not included
in this study, 35% of the patients suffered from a
12-month comorbid diagnosis of depression.31 All
patients were free of psychotropic medication. For
categorical association studies, control subjects
matched 1:1 by sex (n=277, women 209, men 68;
mean age 28.90±7.67 years) were drawn from a
larger number of screened healthy controls (n=519,
women 361, men 158; mean age 25.61±6.72 years).
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The complete control sample (n=519) was used to
test for association of NPSR rs324981 with dimen-
sional anxiety traits. Absence of mental axis 1
disorders was established by experienced psycholo-
gists on the basis of a structured clinical interview
(Mini International Neuropsychiatric Interview) ac-
cording to the criteria of DSM-IV.30 For both patient
and control groups, panic fear and anxiety sensitivity
were evaluated by German versions of the Agorapho-
bic Cognitions Questionnaire (ACQ)32,33 and Anxiety
Sensitivity Index (ASI).34,35 Cases and controls were
of Caucasian origin. The study was approved of by the
ethics committee of Wu¨rzburg and written informed
consent was obtained from all participating subjects.
Genotyping. To determine the functional NPSR
rs324981 A/T (Asn107Ile) polymorphism, we
amplified DNA isolated from venous blood samples
by PCR using the primers F: 50-GAAGGAAAAAA
ATTAAAAATGAACCTCCCCAGGATTTCAT and R:
50-TTCTACCCAGGAGAAAGCGGGCAGTTTGATGCA,
resulting in an amplicon size of 353 bp. Standard PCR
was carried out in a 20ml volume containing 45–60ng
of genomic DNA, 10pmol of each primer, 200mM
dNTPs, 0.4U Taq DNA Polymerase (Eppendorf,
Hamburg, Germany), 50mM KCl, 1.5mM MgCl2 and
10mM Tris-HCl (pH 8.4). After a 5min denaturation,
35 cycles were carried out consisting of 30 s at 94 1C,
30 s at 66 1C and 60 s at 72 1C, followed by a final
extension time of 10min at 72 1C. Amplicons were
digested with TasI (Fermentas, St Leon-Rot, Germany)
(1U), separated for 2 h on a 15% polyacrylamide gel
and visualized by silver-staining. Hardy–Weinberg
criteria, as calculated by the online program DeFinetti
(http://ihg.gsf.de/cgi-bin/hw/hwa1.pl; Wienker TF
and Strom TM), were fulfilled for genotype
distributions of NPSR rs324981 in all tested samples
(all P-values > 0.05). There were genotyping failures
in 10 patients resulting in a total n of 489 patients
(women 305, men 184) in the discovery sample
available for further analysis.
Statistical analysis. Statistical analyses of allele and
genotype distributions were performed by means of
w2-test as implemented in Haploview version 3.2
and Armitage’s trend test as provided by DeFinetti.
In addition, grouped genotype (AA vs AT/TT)
distribution was statistically analyzed based on our
results pointing toward a dominant model for the T
allele and in analogy to the initial study by Okamura
et al.27 explicitly reporting an underrepresentation
of the homozygous AA genotype in patients with
panic disorder. Both association studies have also
been analyzed jointly using the same procedure;
furthermore, meta-analytic treatment of the studies
was performed: odds ratios (ORs) were calculated as a
measure for effect size; thereafter, the Q-statistic36,37
was applied to assess heterogeneity. Inconsistency
across studies was quantified with I^2 metric (I^2=Q-
df/Q).38 In absence of heterogeneity, ORs were
combined using fixed-effects models;39 if significant
heterogeneity was detected, joint ORs were derived from
random-effects models as denoted in Figures 1a–c.40
Calculations were performed using R version 2.1041
along with the package metafor version 0.5–7.42
Psychophysiological assessment in a behavioral
avoidance test
A total of 264 German patients suffering from panic
disorder and agoraphobia, who were part of the
replication sample (MAC sample), were investigated
in a BAT. Thirty patients were excluded from the
analysis because they did not enter the small, light-
proof chamber, and 29 patients had to be excluded
due to measurement failures. From the remaining
sample of 205 patients, 55 were homozygous NPSR
rs324981 A allele carriers and were compared to the
remaining 150 T allele carriers. The groups did not
differ in gender, w2 = 1.58, P=0.209 (AA: 37 female
and 18 male patients; AT/TT: 114 female and 36 male
patients), and age, F (1, 203) < 1, P=0.80 (AA: 35.18
years±1.57 s.e; AT/TT: 35.62 years±0.87 s.e.). After
arriving at the laboratory, patients were informed
about the procedure before the sensors for recording
of electrocardiogram were attached. During anticipa-
tion, patients were sitting for 10min in front of a
small (75 cm wide, 120 cm long, 190 cm high), dark
chamber with the door open. During exposure,
patients were locked in the chamber and told to stay
as long as possible for a maximum of 10min. During
recovery, patients again sat in front of the opened
chamber for 8min. Patients could terminate the BAT
at any time during the procedure. Patients were
instructed to rate intensity of 13 panic symptoms
and subjective indices of anxiety on a scale from 1 to
10 after each period.
The electrocardiogram was measured using an
Einthoven lead II setup with two standard, electro-
lyte-filled Ag/AgCl electrodes (Marquette Hellige,
Freiburg, Germany). The raw signal was filtered
(8–13Hz band pass) and amplified using a Coulbourn
V75-04 bioamplifier (Coulborn, Du¨sseldorf, Germany)
and continuously digitized with a sampling rate of
100Hz. Heart rate was derived from electrocardio-
gram signal using software provided by ANSLAB.43
Interbeat intervals were checked and corrected
whenever misplaced R-wave triggers had occurred
(due to increased T-waves or movement artifacts)
and converted to heart rate (beats per minute, b.p.m.)
in half-second bins. Mean heart rate was calculated
during anticipation, exposure and recovery. This
part of the study was approved by the ethics
committee of the Technical University of Dresden
and informed consent was obtained from all partici-
pating subjects.
To test effects of genotype on symptom reports
and autonomic arousal, we applied a mixed-model
analysis of variance including genotype (AA vs AT/
TT) as a between-subjects factor and block (anticipa-
tion vs exposure vs recovery) as a within-subjects
factor. All statistical tests used a significance level
of P<0.05.
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Functional imaging during presentation of
emotional stimuli
Twenty patients with panic disorder were investi-
gated using an imaging genetic approach (women 12,
men 8; mean age 36.75±9.39 years). Panic disorder
was diagnosed by experienced psychiatrists on the
basis of medical records and a structured clinical
interview (SKID-I) according to the criteria of DSM-
IV.30 Only patients with primary panic disorder were
included, secondary lifetime diagnoses were social
phobia in 10 and major depression in 5 patients.
Ten patients were treated with a selective serotonin
reuptake inhibitor, the other 10 patients were free of
medication. This part of the study was approved
by the local ethical committee in Muenster and
informed consent was obtained from all participating
subjects.
Technical details of fMRI data acquisition and
processing have been reported in detail pre-
viously.44,45 Briefly, subjects viewed 30 s blocks of
alternating emotional (fearful, angry, happy, neutral)
faces46 or a no-face control stimulus (gray rectangle).
Emotional stimuli were presented twice per second in
a random sequence for 500ms. T2* functional data
were acquired at a 3 Tesla scanner (Gyroscan Intera
3.0T; Philips Medical Systems, Best, NL, USA; matrix
128 128, resolution 1.75mm 1.75m 3.5mm; re-
petition time=3 s, echo time=30ms, flip angle = 901).
Functional imaging data were preprocessed (motion
corrected, normalized to standard MNI space and
smoothed) with a published protocol using SPM5
(Wellcome Department of Cognitive Neurology,
London, UK). Statistical analysis was performed by
modeling the different conditions (fearful, angry,
happy, neutral, no face) as variables within the
context of the general linear model (modeled with a
standard hemodynamic response function). Subject-
specific contrasts, reflecting emotion-related activa-
tion (F, A, H and N vs no face), were entered into a
random-effects analysis. Voxel values of 52 pre-
defined regions of interest (ROIs)47 were extracted on
the basis of a priori hypotheses regarding potential
involvement of these regions in emotional stimuli
processing (amygdala, orbitofrontal cortex, ventrome-
dial prefrontal cortex, dorsolateral prefrontal cortex,
anterior cingulate cortex), summarized by mean and
tested among the different conditions using the
MarsBaR toolbox.48 Contrast values were used for
further analyses. To depict activations on anatomical
MRI slices, we applied the Wake Forest University
PickAtlas for the same regions. The statistical thresh-
old was set at P<0.001 (uncorrected) with clusters
defined by at least 10 contiguous voxels of significant
response. To test effects of genotype on activation
in brain ROIs, we applied a multivariate analysis
of variance including genotype (AA vs AT/TT) as a
between-subjects factor and four contrast values
(fearful, angry, happy, neutral vs no faces) as a
within-subjects factor. There were no statistically
detectable differences in medication with selective
Figure 1 NPSR rs324981 and panic disorder: Forest plot showing analyses of TT/TA vs AA in the combined sample (a),
females (b) and males (c).
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serotonin reuptake inhibitors (P=0.639), sex
(P=0.085) and comorbidity with major depression
(P=0.787) or social phobia (P=0.639) across NPSR
genotype groups as calculated by w2-test. However,
because genotype groups differed for age (T=2.456,
P=0.024), age was included as a covariate in all
further tests. All statistical tests used a significance
level of P<0.05.
Results
Association studies with panic disorder
Allele and genotype frequencies of NPSR rs324981 in
patient and control samples are given in Table 1. In
the discovery MMWBG sample, the NPSR rs324981
AA genotype as compared to carriers of at least one T
allele was underrepresented in patients with panic
disorder (P=0.003). Stratification for gender revealed
that this effect held true for both genders; however, it
was more pronounced in the female subgroup of
patients (women: P=0.03; men: P=0.05) (see Table 1).
In an attempt to replicate the association of NPSR
rs324981 with panic disorder, we interrogated a
second, independent case–control sample of 277
patients suffering from panic disorder with agorapho-
bia (MAC sample), along with matched controls
(Table 1). Genotyping procedures and statistical
analyses were identical to the discovery sample.
Again, the NPSR rs324981 AA genotype was signifi-
cantly underrepresented in female patients with
Table 1 NPSR rs324981 A/T polymorphism and panic disorder: association studies
AA AT TT Armitage’s
trend test
AA AT/TT w2-Test A T w2-Test
MMWBG sample
Overall sample
Patients (N=489) 134 229 126 OR=1.32
w2 = 10.38
P=0.001
134 355 OR=1.50
95%CI= 1.14–1.96
w2 = 8.56
P=0.003
497 481 OR=1.35
95%CI= 1.13–1.62
w2 = 11.20
P=0.001
Controls (N=499) 180 222 97 180 319 582 416
Females
Patients (N=305) 92 134 79 OR=1.34
w2 = 7.13
P=0.008
92 213 OR=1.45
95%CI = 1.04–2.02
w2 = 4.71
P=0.030
318 292 OR=1.38
95%CI= 1.10–1.73
w2 = 7.95
P=0.005
Controls (N=312) 120 135 57 120 192 375 249
Males
Patients (N=184) 42 95 47 OR=1.30
w2 = 3.29
P=0.069
42 142 OR=1.60
95%CI = 1.01–2.53
w2 = 3.99
P=0.046
179 189 OR=1.31
95%CI= 0.98–1.75
w2 = 3.34
P=0.068
Controls (N=187) 60 87 40 60 127 207 167
MAC sample
Overall sample
Patients (N=277) 74 140 63 OR=1.20
w2 = 2.16
P=0.141
74 203 OR=1.19
95%CI= 0.83–1.73
w2 = 0.89
P=0.347
288 266 OR=1.19
95%CI= 0.94–1.51
w2 = 2.09
P=0.148
Controls (N=277) 84 144 49 84 193 312 242
Females
Patients (N=209) 50 111 48 OR=1.36
w2 = 4.80
P=0.028
50 159 OR=1.57
95%CI = 1.02–2.40
w2 = 4.24
P=0.039
211 207 OR=1.35
95%CI= 1.03–1.77
w2 = 4.63
P=0.031
Controls (N=209) 69 104 36 69 140 242 176
Males
Patients (N=68) 24 29 15 OR=0.83
w2 = 0.74
P=0.389
24 44 OR=0.51
95%CI = 0.24–1.11
w2 = 2.91
P=0.088
77 59 OR=0.81
95%CI= 0.50–1.31
w2 = 0.73
P=0.394
Controls (N=68) 15 40 13 15 53 70 66
Bold values are significant P-value at significance level of < 0.05.
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panic disorder, whereas there was no significant
effect in the male or the total sample (see Table 1).
When both samples were analyzed jointly in a
meta-association approach leading to a combined
sample size of 766 patients and 776 controls, there
was a highly significant association of the NPSR
rs324981 risk genotypes containing at least one T
allele with disease in the total sample (Armitage’s
trend test OR 1.28, w2 = 12.11, P=0.0005) as well as in
the female (Armitage’s trend test OR 1.35, w2 = 11.95,
P=0.00055), but not the male subsample (Armitage’s
trend test OR 1.15, w2 = 1.25, P=0.263). As such a
meta-association approach might bear several proble-
matic issues, such as ethnic background admixture
(although this is unlikely as both samples were
ascertained in Germany), we also treated the data in
a meta-analytic manner (see Figure 1). Association of
the NPSR rs324981 T risk allele with panic disorder
was confirmed in this meta-analysis, yielding an OR
of 1.38 (P=0.004), which held true in the female (OR
1.49, P=0.004), but not the male subsample (OR 0.95,
P>0.1).
Association study with dimensional anxiety traits
Next, we examined whether the NPSR rs324981 T
allele also influences dimensional constructs asso-
ciated with panic disorder and agoraphobia. To do so,
we tested whether the ACQ and ASI were associated
with NPSR rs324981 in patients from the MAC study
as well as 519 healthy controls. Although there was
not a significant association in control subjects (ACQ,
P=0.41; ASI, P=0.99), the ASI (but not the ACQ; best
P=0.31) score was significantly associated with
genotype in the expected direction in patients:
whereas NPSR rs324981 AA carriers had an ASI
score of 27.5±11.1, T allele carriers displayed a score
of 32.1±11.7 (P=0.002) (see Figure 2). Again, the
difference was due to the female subsample (27.0±
11.7 vs 32.6±11.8, P=0.001) and not present in the
male subsample (28.6±11.8 vs 30.2±11.2, P=0.29).
Genetic modulation of heart rate and symptom reports:
behavioral avoidance test
Genotype groups (AA=55, AT=102, TT=48) did not
differ significantly in duration of exposure, Group
F(1, 203) < 1, P=0.33 (AA: 539.98 s±22.74 s.e; AT/TT:
514.00 s±13.77 s.e). As expected, mean heart rate and
symptom reports significantly increased from antici-
pation to exposure and decreased again during
recovery (Block F(2, 406) = 28.69, P<0.001; Block
F(2, 406) = 90.42, P<0.001 for heart rate and symptom
reports, respectively) showing that the BAT reliably
induced intense fear in this group of patients.
NPSR rs324981 genotype systematically modulated
these response patterns. Homozygous A allele carriers
showed significantly lower overall heart rate than T
allele carriers, Group F(1, 203) = 6.39, P<0.05, which
was not modulated by conditions (Figure 3), thus
depicting an overall larger arousal response during
all three phases of the BAT. Symptom reports were
also significantly modulated but showed a different
Figure 2 NPSR rs324981 A/T polymorphism and anxiety
sensitivity. Closed bars, patients; open bars, controls;
*** = significant at P=0.002.
Figure 3 Mean heart rate (upper panel; a) and mean
symptom intensity (lower panel; b) during anticipation,
exposure and recovery in homozygous A allele carriers and
T allele carriers, respectively.
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pattern. While A and T allele carriers did not differ
in their symptom reports during anticipation and
recovery, T allele carriers reported significantly more
intense symptoms during acute exposure,
BlockGroup F(2, 406) = 4.26, P<0.05.
Genetic modulation of fear circuit activation
We observed association of NPSR rs324981 with brain
activation responses to fearful faces in contrast to
the no-face condition (Figure 4): the protective AA
genotype was found to be associated with an
increased activation in the dorsolateral prefrontal
cortex (left: AA: mean=0.221, s.d. = 0.097; AT/TT:
mean=0.025, s.d. = 0.285; F = 3.857, P=0.042; right:
AA: mean=0.193, s.d. = 0.170; AT/TT: mean=0.048,
s.d. = 0.306; F = 4.182, P=0.033) and lateral orbito-
frontal cortex (left: AA: mean=0.267, s.d. = 0.124;
AT/TT: mean=0.092, s.d. = 0.251; F= 2.621, P=0.102;
right: AA: mean=0.243, s.d. = 0.243; AT/TT:
mean=0.044, s.d. = 0.259; F =3.674, P=0.047),
whereas carriers of at least one T risk allele exhibited
a significantly decreased activity in the anterior
cingulate cortex (left: AA: mean=0.037, s.d. =
0.352; AT/TT: mean=0.255, s.d. = 0.408; F= 4.880,
P=0.021; right: AA: mean=0.009, s.d. = 0.301; AT/TT:
mean=0.197, s.d. = 0.402; F= 5.962, P=0.011).
No other ROIs including the amygdala were found to
be associated with NPSR rs324981 at the corrected
threshold in response to fearful faces. There was no
significant impact of NPSR rs324981 on responsiveness
in any of the ROIs to happy, angry or neutral faces.
Discussion
In this study, association of the more active NPSR
rs324981 T allele with the categorical diagnosis of
panic disorder with and without agoraphobia was
observed in two independent, large case–control
studies as well as in a meta-analytic approach. This
finding strengthens recent evidence arising from
animal models for a pivotal role of NPS in the
expression of anxiety3–7,9–11,49 and for a risk locus on
chromosome 7p14 containing the NPSR gene in panic
disorder.22–24,27
Interestingly, in both samples comprising a total of
766 patients association of NPSR gene variation with
panic disorder strongly originated from or was even
restricted to the female subgroup of patients (n=514).
This finding is in line with previous molecular
genetic reports of female-specific association findings
in panic disorder possibly through hormonal interac-
tions or female-specific transcriptional patterns.50–52
From an evolutionary perspective, one might spec-
ulate that the evolutionarily ‘newer’ T allele variant
might convey a beneficial effect by optimizing the
fight-or-flight reaction through increased arousal
levels, which might be positive in more male-
dominant predatory environments such as hunting,
but not in comparatively safe agricultural or house-
hold environments. The present female-dominant
finding is contrary to the observation by Okamura
et al.27 who reported an association of NPSR rs324981
with panic disorder in the male subgroup of patients
only. However, as their male subsample of patients
was very small (n=51) and NPSR rs324981 genotype
distribution in male control subjects did not conform
to Hardy–Weinberg equilibrium, this observation is
finally inconclusive. Nevertheless, population-speci-
fic differences across Caucasian and Asian samples,
as already observed for other polymorphisms, may
explain this discrepancy.53
Association of the gain-of-function NPSR rs324981
T allele with panic disorder in humans seems
inconsistent with findings in rodent models, where
Figure 4 NPSR rs324981 A/T (Asn107Ile) effects on brain activation during processing of fearful faces (vs no face).
(a) Contrast values analyzed by MarsBaR; (b) ROI analyses of the same regions using the Wake Forest University Pick Atlas
(patients homozygous for the A allele vs patients with AT and TT genotypes at P<0.001). AMY, amygdala; DLPFC,
dorsolateral prefrontal cortex; OFC, orbitofrontal cortex; vmPFC, ventromedial prefrontal cortex; ACC, anterior cingulate
cortex.
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NPS and agonists at NPSR have been shown to rather
exert a dose-dependent anxiolytic effect in the open
field, the light-dark box, the elevated plus maze and
marble-burying paradigms3 (although it should be
noted that pharmacological interventions during
adulthood do not readily mimic genetically driven
alterations during ontogeny). A possible explanation
of this paradox might be that panic disorder is to a
great extent conferred through an increased level
of arousal,54–56 which in animal models has been
found to be driven by increased NPS activity with
a potentially differential dose-dependent effect on
arousal and anxiety, respectively.1,3–5 Increased arou-
sal mediated by the more active T allele would be
in line with Smith et al.57 reporting NPS to cause a
significant stimulation of the hypothalamic-pituitary-
adrenal axis with an increase in plasma adrenocorti-
cotropic hormone and corticosterone along with
increased arousal-like behavior in rats. This hypoth-
esis of increased arousal possibly mediating the
anxiety-increasing effect of NPSR gain-of-function
gene variation is substantiated by several translational
findings at different levels in this study.
The NPSR rs324981 T risk allele was observed to
be associated with increased anxiety sensitivity
as measured by the ASI. Anxiety sensitivity is a
dimensional construct measuring the extent to which
individuals believe that symptoms of arousal and
anxiety can have harmful somatic, social or psycho-
logical consequences.35 Several studies provide evi-
dence for anxiety sensitivity predicting fear responses
to bodily sensations increasing physiological arou-
sal58; for example, following a stair-stepping task59
or hyperventilation challenge,60 during detection of
changes in pulse transit time61 or in response to
caffeine administration62 and ASI seems to be a
predictor for the development of panic disorder after
periods of stress.63 So, the observed association of the
NPSR rs324981 T risk allele with increased anxiety
sensitivity might in part reflect an increased level of
arousal. In addition, individual anxiety sensitivity
profiles seem to discriminatively characterize specific
panic disorder subtypes because in patients with
panic disorder high scores on the ASI have been
reported to be associated with the respiratory subtype
of panic disorder64 and to predict symptomatological
reaction to CO265 as well as increased subjective fear
during hyperventilation challenge.66 Given that pa-
tients with the respiratory subtype of panic disorder
are characterized by a particularly high familial
loading of panic disorder and thereby a potentially
higher genetic vulnerability,67 NPSR gene variation
associated with high anxiety sensitivity in patients
with panic disorder might in part reflect vulnerability
toward this particular subtype of patients with panic
disorder, which, however, remains to be elucidated in
future studies. Finally, women with panic disorder
score higher than men on the AS physical concerns
subscale,68 and anxiety sensitivity has been shown to
be heritable particularly in women.69 So, the present
finding of NPSR gene variation to be associated with
the categorical diagnosis of panic disorder particu-
larly in female patients might in part be explained by
its association with the dimensional phenotype of
anxiety sensitivity restricted to female patients.
The NPSR rs324981 T risk allele was related to
overall increased heart rate during exposure but
also during anticipation and even recovery during a
BAT. These data are consistent with the notion that
patients who carry the T risk allele have an enhanced
sympathomimetic activation and consequently arou-
sal level. In challenging situations in which the
arousal response further increases over an already
elevated baseline level, these patients are more prone
to experience panic symptoms. These findings are
in line with modern learning theories of panic
disorder,55 postulating that internal cues of elevated
arousal increase the chance of experiencing another
panic attack once they have been associated with
aversive responses.70 These data suggest that not only
conditioned anxious apprehension but also genetic
risk factors contribute to the increased arousal level
and might therefore uncover an important missing
link in the understanding of the mechanisms
involved in the development of a panic disorder.
We observed an NPSR rs324981 genotype-depen-
dent brain activation pattern in response to anxiety-
relevant emotional stimuli. The NPSR rs324981 T risk
allele was found to be associated with significantly
decreased activity in the anterior cingulate cortex.
This result is in line with previous studies reporting
anterior cingulate cortex volume reduction in patients
with panic disorder71,72 and diminished cingulate
activity in patients with panic disorder during
identification of fearful facial affect compared to
healthy controls.73 Decreased cingulate cortex activity
has been hypothesized to be due to a chronic
hyperarousal in patients with panic disorder,74 be-
cause decreased cingulate cortex activity appears to
be associated with engagement of arousal networks
particularly during processing of threat-related sti-
muli also in other anxiety disorders such as simple
phobias and posttraumatic stress disorder.75–78 Given
that NPS has been found to dose-dependently elicit
increased arousal response as detailed above, the
NPSR rs324981 T allele increasing NPSR expression
and NPS efficacy at NPSR might confer a heightened
risk of panic disorder through an elevated level
of arousal as reflected by decreased cingulate cortex
activity. In addition, homozygosity for the A allele
was associated with significantly increased activity in
the dorsolateral prefrontal and orbitofrontal cortex
during the processing of fearful faces compared to
activation in T risk allele carriers. Given the well-
established role of the prefrontal and orbitofrontal
cortex to attenuate an emotional response to fear/
threat-related stimuli in anxiety disorders by inhibi-
tion of amygdala activation thorough a top-down
mechanism,13–15,78 increased activity in those regions
might contribute to the observed protective effect of
the NPSR rs324981 AA genotype with respect to
panic disorder.
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Several limitations of this study have to be
considered: Patients and controls in the discovery
and replication samples were not completely matched
for age in that some of the control subjects still are at
risk to develop panic disorder. This, however would
bias against an association finding and not favor a
false-positive finding. Indeed, this may even explain
the somewhat weaker association in the replication
sample as here the age difference was larger. Also,
the discovery and replication sample differed with
respect to the ratio of panic disorder patients with and
without agoraphobia with a smaller agoraphobia ratio
in the discovery sample possibly. Furthermore,
comorbid depression might constitute a confounding
factor, particularly, because the discovery and the
replication samples differed in the rate of comorbid
depression. A further limitation of this study is that
no non-Caucasian populations were investigated
rendering comparison to the study by Okamura
et al.27 difficult. However, although in all samples
Caucasian ancestry was ascertained, ethnic stratifica-
tion even within the German population cannot be
excluded,79 particularly because no genomic control
has been performed in the presently investigated
samples. The effect of genotype on the ASI is only
found in patients, but not in controls. One possible
explanation may be the small variation of anxiety
sensitivity in our supranormal control sample. Final-
ly, caution and restraint is necessary in the inter-
pretation of the imaging genetic part of the study,
given a relatively small number of patients and an
explorative statistical approach not corrected for
multiple testing. Apart from significantly decreased
activity in the anterior cingulate cortex in response to
fearful faces, P-values would not withstand Bonferro-
ni correction for the four multivariate analysis of
variances that were performed for the four different
contrasts (fearful, angry, happy, neutral vs no faces)
over all ROIs resulting in a corrected P-value of
0.0125 (two-sided) or 0.025 (one-sided), respectively,
which might reflect a possible type I error. However,
as largely debated, Bonferroni correction might be too
conservative for strictly hypothesis-driven studies as
the present one and actually increase the probability
of a type II error. A further limitation is that the small
sample size did not allow for meaningful statistical
analyses in subsamples stratified for gender, which,
given a female-dominant result in the categorical
association studies, would have been of interest also
in the imaging genetic part of this study. Furthermore,
although no biased distribution of gender, medication
with selective serotonin reuptake inhibitors and
comorbidity with major depression or social phobia
across NPSR genotype groups could be discerned,
these factors still could constitute possible confound-
ing factors in the evaluation of emotional processing.
For instance, either single dose or subchronic (7–21
days) medication with selective serotonin reuptake
inhibitors has been shown to attenuate amygdala,
hippocampus and medial prefrontal cortex response
to aversive facial expression.80–82 Thus, besides a
potential ceiling effect due to generally increased
baseline amygdala activity in patients with panic
disorder, this may partly explain why no amygdala
activation could be observed as with previous studies
in this sample.44 In addition, patients with social
phobia tend to evaluate neutral faces as potentially
threatening and more aversive than healthy controls
or possibly also patients with pure panic disorder,83
which might have influenced the present results.
Future studies will have to elucidate the mechanisms
by which genetic variation of NPSR modulates the
sympathomimetic system, cingulate and orbito/pre-
frontal cortex activity and their possible functional
interactions. One such mechanism may be mediated
by the startle reflex, which therefore is currently
under investigation in our group.
In summary, the present body of research provides
converging lines of evidence for a role of NPSR gene
variation in the pathogenesis of panic disorder. The
more active NPSR rs324981 T allele (Ile107) has been
found to be associated with the categorical phenotype
of panic disorder in a female-dominant manner,
possibly mediated through increased arousal levels
as reflected by elevated anxiety sensitivity, increased
autonomic arousal as well as distorted processing
of fear-related emotional stimuli. In synopsis with
previous evidence from animal models, these find-
ings might nourish future studies exploring a poten-
tially beneficial use of therapeutic agents targeting the
NPS system in anxiety disorders.
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